Myth: It’s just heartburn.
Fact: Chronic heartburn and GERD can lead to esophageal cancer—even if you’re effectively controlling your symptoms with medication.
EsoGuard accurately detects precancerous cells in the esophagus1, 2, 3 early, so you can take action before they turn into something more serious.
We accept most insurance plans
Fact: Esophageal cancer is the #1 increasing cancer diagnosis and the #2 deadliest form of cancer in the U.S. 4
Esophageal Adenocarcinoma (EAC) has increased over 500% in the past 4 decades. 5, 6
Fact: The disease that leads to esophageal cancer is treatable
EsoGuard has unprecedented detection rates for precancer, so you can take action before cells become cancerous.
Developed through the National Cancer Institute
See if EsoGuard is right for you
How it works
Complete our medical questionnaire
Create your account and fill out a brief intake survey.
Meet virtually with a physician
During your telehealth visit, your provider will determine if EsoGuard is right for you and order the test if indicated.
Get tested
You will be contacted to schedule an in-person office visit where a clinician will administer the test. Results will be available within 3 weeks.
Risk Factors
Some patients are at increased risk for developing esophageal precancer and cancer. If you meet 3 or more of the below criteria, you should get tested:
Chronic heartburn or GERD
Male
50+ years old
Obesity
White
History of tobacco smoking
Family history of Barrett’s Esophagus or Esophageal Cancer
Frequently Asked Questions
Where can I get the EsoGuard test?
If your physician determines EsoGuard is right for you during your telehealth consultation, they will prescribe an in-office visit for the test. The test takes less than 5 minutes to complete.
How soon will I get my results back?
Your test results will be available within a few weeks.
How much does the EsoGuard test cost?
We accept most forms of insurance. Please contact our care team at (877) 202-8469 for more information.
Take control of your health with EsoGuard
References:
1. Moinova, Helen R et al. “Multicenter, prospective trial of non-endoscopic biomarker-driven detection of Barrett’s Esophagus and Esophageal Adenocarcinoma.” The American Journal of Gastroenterology (2024): 10-14309.
2. Greer, Katarina B et al. “Non-endoscopic screening for Barrett’s Esophagus and Esophageal Adenocarcinoma in at risk veterans.” medRxiv (2024): 2024-03
3. Shaheen, N., et al., Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population. medRxiv, 2024: p. 2024.06.24.24309401.
4. American Cancer Society. Cancer Facts & Figures 2025.
5. Hang Thuy-Van Petal. "The Epidemiology of Esophageal Adenocarcinoma in the United States: Presidential Poster Award: 333." American Journal of Gastroenterology 113 (2018): S185-S186
6. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
